Article
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.
JAMA - 20 Aug 2024
Fang Wenfeng, Zhao Yuanyuan, Luo Yongzhong, Yang Runxiang, Huang Yan, He Zhiyong, Zhao Hui, Li Mingjun, Li Kai, Song Qibin, Du Xiaobo, Sun Yulan, Li Wei, Xu Fei, Wang Zhiyu, Yang Kunning, Fan Yun, Liu Baogang, Zhao Hongyun, Hu Ying, Jia Li, Xu Shen, Yi Tienan, Lv Dongqing, Lan Haitao, Li Mengxia, Liang Wenhua, Wang Yongsheng, Yang Hui, Jia Yuming, Chen Yuan, Lu Junguo, Feng Jifeng, Liu Chunling, Zhou Ming, Zhou Jianya, Liu Xianling, Zhou Ningning, He Ming, Dong Xiaorong, Chen Hualin, Chen Yongxing, Su Haichuan, Li Xiaoling, Zhang Zhihong, Yang Lei, Cheng Ying, Chen Likun, Hou Xue, Zhang Yu, Guo Jun, Wang Zhen, Lu Hong, Wu Di, Feng Weineng, Li Wen, Huang Jianan, Wang Yan, Song Xia, Peng Jiewen, Liu Laiyu, Guo Yubiao, Li Wenting, Lu Dongmei, Hu Mingxiu, Wang Zhongmin Maxwell, Li Baiyong, Xia Michelle, Zhang Li
Abstract excerpt
Importance: For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. Objective: To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with the epidermal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.